Related Experiment Video

Updated: May 17, 2026

Spatial and Temporal Control of Murine Melanoma Initiation from Mutant Melanocyte Stem Cells
06:09

Spatial and Temporal Control of Murine Melanoma Initiation from Mutant Melanocyte Stem Cells

Published on: June 7, 2019

Second primary melanomas on treatment with vemurafenib: reply from the authors

L Fearfield, J A Newton-Bishop, R Sinha

    The British Journal of Dermatology
    |October 17, 2012
    PubMed
    Abstract

    No abstract available in PubMed .

    More Related Videos

    Ex Vivo Treatment Response of Primary Tumors and/or Associated Metastases for Preclinical and Clinical Development of Therapeutics
    08:29

    Ex Vivo Treatment Response of Primary Tumors and/or Associated Metastases for Preclinical and Clinical Development of Therapeutics

    Published on: October 2, 2014

    Analysis of Lymph Node Volume by Ultra-High-Frequency Ultrasound Imaging in the Braf/Pten Genetically Engineered Mouse Model of Melanoma
    08:18

    Analysis of Lymph Node Volume by Ultra-High-Frequency Ultrasound Imaging in the Braf/Pten Genetically Engineered Mouse Model of Melanoma

    Published on: September 8, 2021

    Related Experiment Videos

    Last Updated: May 17, 2026

    Spatial and Temporal Control of Murine Melanoma Initiation from Mutant Melanocyte Stem Cells
    06:09

    Spatial and Temporal Control of Murine Melanoma Initiation from Mutant Melanocyte Stem Cells

    Published on: June 7, 2019

    Ex Vivo Treatment Response of Primary Tumors and/or Associated Metastases for Preclinical and Clinical Development of Therapeutics
    08:29

    Ex Vivo Treatment Response of Primary Tumors and/or Associated Metastases for Preclinical and Clinical Development of Therapeutics

    Published on: October 2, 2014

    Analysis of Lymph Node Volume by Ultra-High-Frequency Ultrasound Imaging in the Braf/Pten Genetically Engineered Mouse Model of Melanoma
    08:18

    Analysis of Lymph Node Volume by Ultra-High-Frequency Ultrasound Imaging in the Braf/Pten Genetically Engineered Mouse Model of Melanoma

    Published on: September 8, 2021

    Related Concept Videos

    Treatment Resistant Cancers02:56

    Treatment Resistant Cancers

    Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
    Skin Cancer01:30

    Skin Cancer

    Skin cancer is a type of cancer that occurs when there is an abnormal growth of skin cells, usually triggered by damage to the DNA within the skin cells. It is primarily caused by exposure to ultraviolet (UV) radiation from the sun or artificial sources like tanning beds. Skin cancer is the most common type of cancer worldwide, and its incidence continues to rise.
    Basal Cell Carcinoma (BCC): BCC is the most common type of skin cancer, accounting for about 80% of cases. It typically develops in...

    Articles linked to this work by shared authors, journal, and citation graph.

    Efficacy and safety of stereotactic radiosurgery in the management of brain metastases in patients with metastatic melanoma.

    The British journal of radiology·2026

    Retreatment, rechallenge, and escalation with subsequent immune checkpoint inhibitor therapies across cancers after initial failure.

    ESMO open·2025

    Defining Standard Data Reporting in Pelvic Exenterations for Non-Rectal Cancers: A Systematic Review of Current Data Reporting.

    Cancers·2025

    Fatal intracranial haemorrhage shortly after belzutifan initiation in von Hippel-Lindau (VHL) disease-associated haemangioblastoma.

    ESMO open·2025

    Search for a Hidden Sector Scalar from Kaon Decay in the Dimuon Final State at ICARUS.

    Physical review letters·2025

    Efficacy of adjuvant therapy in patients with stage IIIA cutaneous melanoma.

    Annals of oncology : official journal of the European Society for Medical Oncology·2025

    Non-Invasive Biomarker Models for Objective Severity Assessment and Detection of Subclinical Inflammation in Non-Lesional Atopic Dermatitis.

    The British journal of dermatology·2026

    Commensal Skin Microbiota Modulate Responses to Ultraviolet Radiation in Humans.

    The British journal of dermatology·2026

    Real-world effectiveness of topical ruxolitinib in non-segmental vitiligo: repigmentation, mental health, and quality-of-life outcomes in an 860-patient multicentre study.

    The British journal of dermatology·2026

    Assessment of Natural Killer Cell Serial Degranulation.

    Current protocols·2026

    Oncogenic KRAS Rewires mRNA Stability and Translation through AGO2-Mediated Disruption of the miRNA pathway.

    Cancer research·2026

    Stimuli-responsive nanocarriers for precision cation channel therapy.

    Chemical communications (Cambridge, England)·2026

    Disruption of hippocampal upstream regulators of mTOR and insulin pathways in Down syndrome with Alzheimer's disease neuropathology: Preliminary observations.

    Alzheimer's & dementia : the journal of the Alzheimer's Association·2026

    ATF7 drives diabetic wound healing via NOTCH1 repression and N1ICD-dependent macrophage polarization control.

    JCI insight·2026

    Innate immune sensor NOD2 promotes cartilage degradation and osteoarthritis progression by stabilizing TRAF6 in chondrocytes.

    JCI insight·2026
    See all related articles
    JoVE
    x logofacebook logolinkedin logoyoutube logo
    ABOUT JoVE
    OverviewLeadershipBlogJoVE Help Center
    AUTHORS
    Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
    LIBRARIANS
    TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
    RESEARCH
    JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
    EDUCATION
    JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
    Terms & Conditions of Use
    Privacy Policy
    Policies
    Jove
    Visualize
    Contact Us